J&J Completes Zarnestra Submission For Leukemia Under Pilot 1 Program
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
HGS Lymphostat-B Is 1 Of 7 Agents Selected For FDA’s Pilot 2 CMA Program
FDA has selected Human Genome Sciences’ lupus biologic Lymphostat-B for the continuous marketing application (CMA) Pilot 2 program, HGS announced March 4.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product